TomoTherapy and Medical Intelligence Announce Strategic Partnership at ASTRO

Companies Preview Jointly Developed Fixation and Repositioning Device for CT-Guided, Helical Stereotactic Radiosurgery

MADISON, Wis. — TomoTherapy Incorporated (NASDAQ: TTPY) announced today that it has partnered with Medical Intelligence, an Elekta company, to enhance the TomoTherapy^® Hi·Art^® treatment system’s stereotactic radiosurgery capabilities. A head frame fixation and repositioning device, is on display in the TomoTherapy booth at the Annual Meeting of the American Society of Therapeutic Radiology and Oncology (ASTRO), which opened Sunday and runs through Wednesday, October 31, 2007. This is a works-in-progress prototype of the first product to be developed through the partnership.

“We are pleased to welcome Medical Intelligence as a strategic partner,” said Del Coufal, vice president of marketing for TomoTherapy. “Medical Intelligence joins a number of companies who have signed on to develop products for the Hi·Art treatment system. As providers of this next-generation platform, it is important for TomoTherapy to work with industry innovators as we deliver the tools our customers need to continue advancing the state of cancer care.”

Since 2003, more than 150 TomoTherapy Hi·Art treatment systems have been installed in cancer treatment centers around the world. The system is unique among radiation therapy devices because it integrates CT imaging and a helical delivery pattern for increased accuracy and precision of intensity-modulated radiation therapy (IMRT). Increasingly, clinicians have also used the Hi·Art system for stereotactic radiosurgery (SRS) and stereotactic radiation therapy (SRT), where high doses of precisely targeted radiation are delivered in a single or a few treatment fractions.

Said Christian Hieronimi, managing director of Medical Intelligence, “We see this as an excellent opportunity to help enhance the clinical functionality of the TomoTherapy Hi·Art system. In combination with our equipment and expertise in the SRS field, more patients worldwide will benefit from the TomoTherapy treatment process.”

About TomoTherapy Incorporated

TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art^® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD^™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile^™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

Forward-Looking Statements

Statements in this release regarding future products, events, expectations and other similar matters, including but not limited to statements using the terms “can,” “will” or “expect” constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to risks inherent in the development and commercialization of new technology and products, and the other risks listed from time to time in TomoTherapy’s filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy’s judgments as of this date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.

29 Oct 2007

• Recent Company News
• Company News Archives